Poster presented by Dr. Juan Iovanna (Inserm U1068, Marseille, France) at the Annual AACR congress (USA, Washington, 1-6 April 2017)

Discover IMODI’s presentations & poster at the Annual AACR Congress (USA, Washington, 1-6 April 2017)
05/04/2017
New results on the mechanism of drug resistance in AML (Acute Myeloid Leukemia) published in Cancer Discovery by the Team RESISTAML (INSERM U1037) headed by Dr. Jean-Emmanuel Sarry, IMODI Partner
24/04/2017

Poster presented by Dr. Juan Iovanna (Inserm U1068, Marseille, France) at the Annual AACR congress (USA, Washington, 1-6 April 2017)

AACR 2017 - Poster presentation - Abstract # 3846 by Dr. Juan Iovanna (Inserm U1068, Marseille, France)

AACR 2017 - Poster presentation - Abstract # 3846 by Dr. Juan Iovanna (Inserm U1068, Marseille, France)

IMODI initiative : a novel holistic and integrative approach with patient-derived tumor models against pancreatic cancer

Introduction

The national IMODI (Innovative MODels Initiative) consortium includes 25 partners (pharma, SMEs, academic research labs and clinical centers) with the aim of developing more predictive tools to improve the selection of new effective treatments to combat 9 cancer pathologies. These developments include:
  • Collection of in-vivo PDX models,
  • Collection of in-vitro derived cell lines,
  • 2D & 3D ex-vivo assays,
  • In-vivo humanized models (immune system, liver and tumour stroma),
  • Characterization of tumour histology, gene mutations, gene expression, pharmacological responses and gut microbiota,
  • Biobanks of tumours, blood, serum and stools
  • Central database,
  • Datamining,
Results on pancreatic adenocarcinoma model developments, characterization and data analysis are presented as an example of the IMODI holistic and integrative approach.
 
 
Share this